Clinical trials: Inherited Retinal Disease
Retinitis Pigmentosa
Clinical Trial of Lutein for Patients With Retinitis Pigmentosa Receiving Vitamin A
The purpose of this trial is to determine whether lutein in addition to vitamin A will slow the course of retinitis pigmentosa.
- Trial name
- NCT00346333
- Testing
- Lutein, Cornstarch control
- Where
- United States
- Volunteers
- 240 people
- Sponsor
- National Eye Institute (NEI)
Neovascular Age-related Macular Degeneration
A Study to Assess the Efficacy and Safety of AKST4290 With Aflibercept in Patients With Newly Diagnosed nAMD
This study will evaluate the efficacy and safety of AKST4290 in combination with aflibercept injections in subjects with newly diagnosed neovascular age-related macular degeneration (nAMD).
- Trial name
- PHTHALO-205 (NCT04331730)
- Testing
- AKST4290, Aflibercept
- Where
- 21 sites in United States, Germany and 2 more
- Volunteers
- 107 people
- Sponsor
- Alkahest, Inc.
Retinoblastoma
Intra-arterial Chemotherapy for the Treatment of Intraocular Retinoblastoma
The purpose of this study is to show that chemotherapy delivered directly through the artery supplying the eye (ophthalmic artery) to patients with retinoblastoma is a safe and effective treatment alternative to conventional…
- Trial name
- NCT01293539
- Testing
- Melphalan hydrochloride
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Choroideremia
Efficacy and Safety of BIIB111 for the Treatment of Choroideremia
The objective of the study is to evaluate the efficacy and safety of a single sub-retinal injection of BIIB111 in participants with choroideremia (CHM).
- Trial name
- STAR (NCT03496012)
- Testing
- BIIB111
- Where
- 18 sites in United States, Canada and 6 more
- Volunteers
- 169 people
- Sponsor
- Biogen
Retinitis Pigmentosa
A Study in Subjects With Retinitis Pigmentosa
An open-label Phase II clinical trial, 8 (eight) subjects with retinitis pigmentosa due to rhodopsin mutations (including P23H) will be identified and treated with serial intravitreal injections of ADX-2191 in the worse seeing…
- Trial name
- NCT05392179
- Testing
- ADX-2191
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Aldeyra Therapeutics, Inc.
Pain, Retinopathy of Prematurity
Proparacaine and Mydriatic Eye Drops
In this study, we will be evaluating whether premedication with an anesthetic eye drops leads to a decreased sensation of pain when given dilating eye drops prior to eye examinations to evaluate for retinopathy of prematurity in…
- Trial name
- NCT01266824
- Testing
- Proparacaine Hydrochloride Ophthalmic Solution
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Children's Hospital of Philadelphia
Choroideremia
Choroideremia Gene Therapy Clinical Trial
Phase II gene therapy study, involving a total of 6 male patients with choroideremia. The study will be conducted at the Bascom Palmer Eye Institute, University of Miami.
- Trial name
- NCT02553135
- Testing
- Injection of AAV2-REP1 (10e11 vg)
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Byron Lam
Diabetic Retinopathy, Macular Degeneration
Advancing Understanding of Transportation Options
This Stage II randomized, controlled, longitudinal trial seeks to assess the acceptability, feasibility, and effects of a driving decision aid use among geriatric patients and providers.
- Conditions
- Diabetic Retinopathy, Macular Degeneration, Glaucoma, Retinitis Pigmentosa
- Trial name
- AUTO (NCT04141891)
- Testing
- Driving Decision Aid, Older Drivers Website
- Where
- 3 sites in United States
- Volunteers
- 529 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Retinitis Pigmentosa
The Perceptual Experience of Argus II Users
This Basic Experimental Studies Involving Humans (BESH) study investigates phosphene perception and performance factors in blind participants implanted with the Argus II retinal prosthesis system.
- Trial name
- NCT05285618
- Testing
- Argus II
- Where
- 3 sites in United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- University of California, Santa Barbara
Retinopathy of Prematurity
Synergistic Pharmacologic Intervention for Prevention of ROP (SPIPROP Study)
Phase 2, open-label, randomized, multi-center studies in infants and premature infants are necessary to determine treatment and preventative strategies for ROP.
- Trial name
- SPIPROP (NCT02344225)
- Testing
- Caffeine citrate, Ibuprofen, Ketorolac
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- State University of New York - Downstate Medical Center
X-linked Retinoschisis
Safety and Efficacy of rAAV-hRS1 in Patients With X-linked Retinoschisis (XLRS)
This study will evaluate the safety and efficacy of a recombinant adeno-associated virus vector expressing retinoschisin (rAAV2tYF-CB-hRS1) in patients with X-linked retinoschisis.
- Trial name
- NCT02416622
- Testing
- rAAV2tYF-CB-hRS1
- Where
- 9 sites in United States
- Volunteers
- 27 people
- Sponsor
- Beacon Therapeutics
Retinitis Pigmentosa, AMD
Rod Sensitivity in Age-related Macular Degeneration (AMD) and Retinitis Pigmentosa (RP)
A new fundus-guided microperimeter (MP-3S) has been developed by Nidek, Inc. to track the fundus of the patient and present stimuli in specific anatomically-defined locations.
- Trial name
- NCT03322930
- Testing
- Rod sensitivity
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Retina Foundation of the Southwest
Age-related Macular Degeneration
Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON)
This was a 64-week randomized, double-masked, multi-center, active-controlled, two-arm study in patients with neovascular age related macular degeneration (nAMD) who have not previously received anti- vascular endothelial growth…
- Trial name
- TALON (NCT04005352)
- Testing
- Brolucizumab 6 mg, Aflibercept 2 mg
- Where
- 118 sites in United States, Argentina and 18 more
- Volunteers
- 734 people
- Sponsor
- Novartis Pharmaceuticals
Retinopathy of Prematurity, Retinal Detachment
Efficient Study of ACULAR in Inhibiting Proliferative Retinopathy in Prematurity
The purpose of this study is to test whether ACULAR, a nonsteroidal anti-inflammatory eye drop medication, can prevent the development of retinopathy of prematurity (ROP) and/ or decrease its severity.In this study ACULAR will be…
- Conditions
- Retinopathy of Prematurity, Retinal Detachment, Blindness
- Trial name
- ROP (NCT00634972)
- Testing
- ACULAR, REFRESH TEARS
- Where
- United States
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- University of South Alabama
Macular Degeneration, Wet Macular Degeneration
Aflibercept After Ranibizumab in Exudative Age-related Macular Degeneration
The purpose of the current study is to evaluate the ability of Eylea to induce a regression of PED height on patients previously extensively treated by Lucentis.
- Conditions
- Macular Degeneration, Wet Macular Degeneration, Retinal Degeneration, Retinal Diseases
- Trial name
- ARI2 (NCT02157077)
- Testing
- Aflibercept
- Where
- 9 sites in France
- Volunteers
- 84 people
- Sponsor
- Centre Hospitalier Intercommunal Creteil
Von Hippel-Lindau Syndrome
A Phase I/II Trial for Intravitreous Treatment of Severe Ocular Von Hippel-Lindau Disease Using a Combination of the PDGF Antagonist E10030 and the VEGF Antagonist Ranibizumab
Background: People with Von-Hippel-Lindau (VHL) disease may experience significant vision loss as a result of retinal capillary hemangiomas (RCH), the most common and often earliest manifestation of VHL.
- Trial name
- NCT02859441
- Testing
- Ranibizumab, E10030
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- National Eye Institute (NEI)
Retinitis Pigmentosa
Cone Rescue in Retinitis Pigmentosa by the Treatment of Lycium Barbarum
Objectives: To study the immediate effect and the persistent effect of Lycium barbarum (LB) treatment on retinal functions, especially the cone function, and retinal structure in patients with retinitis pigmentosa (RP) Design…
- Trial name
- NCT02244996
- Testing
- Lycium Barbarum
- Where
- Hong Kong
- Volunteers
- 50 people
- Sponsor
- The Hong Kong Polytechnic University
Retinopathy of Prematurity
RAINBOW Study: RAnibizumab Compared With Laser Therapy for the Treatment of INfants BOrn Prematurely With Retinopathy of Prematurity
The purpose of this study was to determine if intravitreal ranibizumab is superior to laser ablation therapy in the treatment of retinopathy of prematurity (ROP).
- Trial name
- RAINBOW (NCT02375971)
- Testing
- Ranibizumab, Laser therapy
- Where
- 86 sites in United States, Austria and 24 more
- Volunteers
- 224 people
- Sponsor
- Novartis Pharmaceuticals
Retinitis Pigmentosa
Safety of Repeat Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Adult Subjects With Retinitis Pigmentosa
The primary objective of the study is to assess the safety of repeat injection of human retinal progenitor cells (jCell) in adult subjects with RP that have previously been treated with jCell.
- Trial name
- NCT04604899
- Testing
- human retinal progenitor cells
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- jCyte, Inc
Retinopathy of Prematurity
Study to Assess the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Compared to Laser Photocoagulation in Patients With Retinopathy of Prematurity
The primary objective of the study is to assess the efficacy of aflibercept compared to laser in patients diagnosed with retinopathy of prematurity (ROP).
- Trial name
- BUTTERFLEYE (NCT04101721)
- Testing
- aflibercept, laser photocoagulation
- Where
- 52 sites in United States, Bulgaria and 11 more
- Volunteers
- 127 people
- Sponsor
- Regeneron Pharmaceuticals